Neuromuscular Blockade

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

BRIDIONApproved

sugammadex

Merck & Co.

intravenous2015

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

MSDIreland - Ballydine

22 programs

Deep neuromuscular blockadePhase 41 trial

RocuroniumPhase 41 trial

Rocuronium BromidePhase 41 trial

SugammadexPhase 41 trial

+17 more programs

Active Trials

NCT04124757Completed731Est. Jun 2024

NCT02925143Completed6,525Est. Jun 2017

NCT03117387Completed250Est. Jul 2020

+19 more trials

Sharp TherapeuticsPA - Pittsburgh

21 programs

Deep neuromuscular blockadePhase 4

RocuroniumPhase 4

Rocuronium BromidePhase 4

SugammadexPhase 4

Sugammadex 2 mg/kgPhase 4

+16 more programs

Merck & Co.RAHWAY, NJ

5 programs

E-learning course in neuromuscular monitoringN/A

Measurements of the level of neuromuscular blockadeN/A

Neuromuscular Blocking AgentN/A

MK-8616PHASE_2

sugammadexPHASE_41 trial

Active Trials

NCT03679611Completed120Est. Oct 2021

Alliance PharmaceuticalsUK - Wiltshire

1 program

SugammadexPhase 41 trial

Active Trials

NCT05661409Completed46Est. Aug 2024

Temple TherapeuticsNetherlands - Geleen

1 program

neostigmine/glycopyrrolatePhase 4

BiocorpFrance - Issoire

1 program

BX1000Phase 21 trial

Active Trials

NCT05687253Completed80Est. May 2023

SenzimeSweden - Uppsala

1 program

neuromuscular blockade monitoringN/A1 trial

Active Trials

NCT03987607Completed50Est. Dec 2019

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Alliance PharmaceuticalsSugammadex

MSDRocuronium Bromide

MSDneostigmine/glycopyrrolate

MSDSugammadex 2 mg/kg

Merck & Co.sugammadex

MSDSugammadex 2 mg/kg

MSDSugammadex 2 mg/kg ABW

MSDSugammadex

MSDRocuronium

MSDsugammadex

MSDDeep neuromuscular blockade

MSDsufficient dose of rocuronium

MSDRocuronium

MSDSugammadex

MSDsugammadex

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 2,968 patients across 19 trials

NCT05661409 Alliance PharmaceuticalsSugammadex

Sugammadex as Rescue Therapy

Start: Jul 2023Est. completion: Aug 202446 patients

Phase 4Completed

NCT05562999 MSDRocuronium Bromide

Impact of Deep Neuromuscular Blockade During Total Hip Replacement Surgery on Postoperative Recovery and Immune Function

Start: Nov 2022Est. completion: Aug 2024100 patients

Phase 4Completed

NCT04606901 MSDneostigmine/glycopyrrolate

Comparison of Time to Extubation Using Sugammadex or Neostigmine

Start: Apr 2021Est. completion: Jul 202358 patients

Phase 4Completed

NCT03909165 MSDSugammadex 2 mg/kg

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

Start: Jul 2019Est. completion: Sep 2023145 patients

Phase 4Completed

NCT03679611 Merck & Co.sugammadex

Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications

Start: Jan 2019Est. completion: Oct 2021120 patients

Phase 4Completed

NCT03351608 MSDSugammadex 2 mg/kg

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

Start: Feb 2018Est. completion: Jan 2020288 patients

Phase 4Completed

NCT03346070 MSDSugammadex 2 mg/kg ABW

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

Start: Jan 2018Est. completion: Jan 2019207 patients

Phase 4Completed

NCT03168308 MSDSugammadex

Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients

Start: Sep 2017Est. completion: Sep 201992 patients

Phase 4Completed

NCT03039543 MSDRocuronium

Neuromuscular Blockade During Transurethral Resection of Bladder Cancer

Start: Jun 2017Est. completion: Nov 2017108 patients

Phase 4Completed

NCT02860507 MSDsugammadex

Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency

Start: Aug 2016Est. completion: Feb 201850 patients

Phase 4Completed

NCT02794714 MSDDeep neuromuscular blockade

Deep vs Moderate Block: Impact on Operating Conditions & Patient Satisfaction

Start: Jun 2016Est. completion: Dec 20170

Phase 4Withdrawn

NCT02724111 MSDsufficient dose of rocuronium

Effect of Neuromuscular Blockade on Operating Conditions and Overall Satisfaction During Spinal Surgery

Start: May 2016Est. completion: Feb 201790 patients

Phase 4Completed

NCT02410590 MSDRocuronium

Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)

Start: Jul 2015Est. completion: Oct 20160

Phase 4Withdrawn

NCT01422304 MSDSugammadex

Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)

Start: Oct 2011Est. completion: Sep 20121,198 patients

Phase 3Completed

NCT01050543 MSDsugammadex

Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)

Start: Feb 2010Est. completion: Aug 2010128 patients

Phase 3Completed

NCT00751179 MSDrocuronium

Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)

Start: Nov 2008Est. completion: Dec 2009161 patients

Phase 3Completed

NCT00656799 MSDsugammadex

Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)

Start: Apr 2008Est. completion: Jul 20096 patients

Phase 3Completed

NCT00535496 MSDsugammadex

Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)

Start: Sep 2007Est. completion: Feb 200891 patients

Phase 3Completed

NCT05687253 BiocorpBX1000

Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery

Start: Oct 2022Est. completion: May 202380 patients

Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

10 late-stage (Phase 3) programs, potential near-term approvals

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.